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Abstract
Most infections by genus Bartonella in immunocompromised patients are caused by B. henselae and B.
quintana. Unlike immunocompetent hosts who usually develop milder diseases such as cat scratch disease and
trench fever, immunocompromised patients, including those living with HIV/AIDS and posttransplant
patients, are more likely to develop different and severe life-threatening disease. This paper will discuss
Bartonella's manifestations in immunosuppressed patients and will examine Bartonella's interaction with the
immune system including its mechanisms of establishing infection and immune escape. Gaps in current
understanding of the immunology of Bartonella infection in immunocompromised hosts will be highlighted.
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Most infections by genus Bartonella in immunocompromised patients are caused by B. henselae and B. quintana. Unlike
immunocompetent hosts who usually develop milder diseases such as cat scratch disease and trench fever, immunocompromised
patients, including those living with HIV/AIDS and posttransplant patients, are more likely to develop diﬀerent and severe life-
threatening disease. This paper will discuss Bartonella’smanifestations in immunosuppressed patients and will examineBartonella’s
interaction with the immune system including its mechanisms of establishing infection and immune escape. Gaps in current
understanding of the immunology of Bartonella infection in immunocompromised hosts will be highlighted.
1. Introduction
In this paper, we present a summary of the basic characteris-
tics of Bartonella species which are important etiologic agents
in human disease. The discussion focuses on a review of what
is known of the immunology of Bartonella, particularly in
immunocompromised hosts.
2. Classification
Bartonella are fastidious hemotropic facultative intracellular
Gram-negative bacteria of the alpha-2 subgroup of Pro-
teobacteria [1, 2]. Of the 24 species that comprise the genus
Bartonella, B. bacilliformis, B. henselae, and B. quintana
infections have been most commonly implicated in human
disease and B. henselae and B. quintana account for the
majority of morbidity and mortality among immunocom-
promised individuals [3–5].
3. Bartonella Epidemiology
Each of the major Bartonella species implicated in human
disease has unique epidemiology. While the vast majority
of Bartonella species have an identified zoonotic reservoir
such as domesticated animals and farm animals, the animal
reservoir for both B. quintana and B. bacilliformis have not
yet been identified. While B. bacilliformis is transmitted by
the sand fly and the major vector for B quintana is the human
body louse, B quintana has also been found in rodent fleas,
including rat fleas, and thus a potential for a rodent vector
has been hypothesized [6, 7].
B. henselae occurs throughout the world. It is a zoonosis
transmitted from the natural reservoir, cats (Felis catus),
usually via cat scratch or bite and less commonly by a vector
such as cat fleas (Ctenocephalides felis) or ticks [8]. Cross-
sectional studies have reported as much as 81% seropositivity
point prevalence among cats in diﬀerent regions of the world.
Bacteremia is more prevalent in cats that are less than 1 year
old [2]. Humans and dogs are accidental hosts.
Although B. quintana occurs worldwide, with improved
sanitation and living conditions, disease caused by B. quin-
tana has dramatically decreased and now occurs primarily in
small epidemics in conditions characterized by crowding and
poor sanitation.
Humans are likely the natural reservoir for B. quintana
which is spread by human body lice (Pediculus humanis
corporis) [8]. Infected body lice excreta on human skin
induce pruritis, and skin breakdown that follows scratching
allows for B. quintana’s pathway of invasion [9].Wild rodents
have also been identified as potential reservoirs [6, 7].
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B. bacilliformis is endemic in mountainous areas of
Peru, Columbia, and Ecuador [10]. It is transmitted by the
Lutzomyia sandfly, but the animal reservoir has yet to be
identified.
4. Bartonella and the Human Immune System
4.1. Establishing Infection: Evasion of the Immune System.
Despite extensive knowledge about the disease syndromes
caused by Bartonella species in humans, little is known about
the humoral and cellular immune mechanisms involved
in establishment and persistence of Bartonella infection in
humans. Experimental studies using B. tribocorum inocula-
tion onto an immune-competent rat model have shown that
the brief bacteremia after inoculation is followed by a 3–5-
day bacteremia-free window before resurgence of persistent
intraerythrocytic bacteremia that lasts for 8–11 weeks [11].
This model highlights possible existence of a sanctuary site
where the initial infection gets established before persistent
intraerythrocytic infection manifests. So far, three such
potential sanctuary sites include (a) extracellular matrix
where high local bacterial replication may be achieved
following initial infection [11], (b) bone-marrow stem cells
such as erythroid progenitor cells where CD34+ cells in the
bone marrow may be infected followed by release of infected
erythrocytes into the blood stream [12] or endothelial
progenitor cells which may also get infected in the bone
marrow prior to their mobilization into circulation for
endothelial repair [13], and, finally, (c) mature endothelial
cells [14].
Bartonella Has Several Characteristics That Lead to Immune
Evasion. Bartonella lipopolysaccaride (LPS) is composed of
a unique combination of Lipid A and long-chain fatty
acids and likely contributes to the bacteria’s ability to
evade the immune system [15]. Empiric data have shown
that Bartonella initially evades the innate immune system
because its surface molecules are not recognized by TLR-4
on dendritic cells or macrophages, [16], thereby allowing for
establishment of what might lead to persistent infection. The
LPS does not induce tumor necrosis factor alpha and has
reduced stimulation of Toll-like receptor 2 (TLR2) and thus
reduced endotoxicity [17, 18]. The LPS of B. quintana may
even antagonize the Toll-like receptor 4 (TLR4) [19], which is
a key component of innate immunity. Popa et al. and Matera
et al. demonstrated that LPS from B. quintana resulted in the
downregulation in human monocytes of nearly all cytokines
normally produced by TLR4 in response to LPS [19, 20] and
B. quintana’s antagonism of TLR4 may be responsible for the
absence of symptoms normally associated with bacteremia
with Gram-negative organisms, such as septic shock.
Furthermore, B. henselae can avoid lysosomal fusion and
acidification after the bacteria invades phagocytes such as
endothelial cells and macrophages. For instance, B. henselae
containing vacuoles (BCVs) had delayed development or
complete lack of typical endocytic markers [21]. When the
BCV contained inert or killed B. henselae, the endocytic
markers were in normal ranges. Such Dendritic cells within
cat scratch disease (CSD) granuloma in immune-competent
humans that are chronically infected with Bartonella are also
able to limit the infection to the same lymph node region
via a localized B-cell-mediated humoral immune activation
that is regulated by dendritic cells [22]. On the contrary,
immunocompromised persons develop bacteremia, and
distant seeding may occur, hence recovery of Bartonella
in cardiac valves, other vasoproliferative lesions (bacillary
angiomatosis or peliosis). Exactly how local bacterial control
is lost in immunocompromised subjects is unclear.
4.2. Bacterial Persistence: Pro- and Anti-Inflammatory Re-
sponse. Historically, clinical and in vitro studies implicated
a Th1 immune response to Bartonella infection. The old
Bartonella skin test involved an intradermal injection of
suppurative material derived from lymph nodes from cat
scratch disease patients and was interpreted as positive if
their skin developed a large erythematous area within 48 hrs.
This test is a classic delayed type hypersensitivity reaction,
mediated through the Th1 immune response. In vitro
studies have also supported the use of a Th1 response with
mice splenocytes showing increased production of the Th1
cytokines IFNγ and IL-12 in response to B. henselea when
compared with controls [23]. The role of innate immunity is
also demonstrated through the repeated evidence of elevated
IL-8 in response to B. henselae [24].
More recent studies have focused on the role of cytokines
in acute and chronic Bartonella infection. Acute infection
in immune-competent subjects with CSD have revealed
upregulation of proinflammatory (IL-2, IL-6) and anti-
inflammatory (IL-10) cytokines [25]. On the contrary, low
CD4 counts (a marker of immune-compromise) have been
associated with elevated IL-10 levels during acute infection
with Bartonella, a cytokine milieu that may allow an acute
infection to persist especially given the anti-inflammatory
nature of IL-10 [16, 25, 26]. Chronic infection is associated
with elevated levels of Interferon-alfa and IL-4 in both animal
[16, 27] and human studies of the bacillary angiomatosis
[16], but not in immune-competent subjects with CSD
[25]. Thus, far, empiric data regarding Bartonella infection
persistence and role in vasoproliferation is better understood
from cytokine profiles, and less so from the traditional roles
of humoral or cellular immunity.
Most of the research in infection involving immuno-
compromised hosts has focused on the establishment of
bacterial stimulated angiogenesis. Understanding of the
immune defense of Bartonella species in immunocompro-
mised patients has been hampered by the lack of good
animal model [28]. Since the response in the competent
immune system involves Th1 and innate immunity through
macrophages, a logical inference can be made that HIV-
positive and other patients deficient in these immunological
areas would have diﬃculty limiting the infection and thus
would develop systemic manifestations. This deduction,
however, has not yet been demonstrated as themechanism by
which HIV facilitates the spread of Bartonella. Chiaraviglio
et al. described a murine model for chronic Bartonella
infection using B. taylorii in SCID/Beige mice (B-, T-, NK-
cell deficient) [29]. The group described that this model
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approximated human bacillary peliosis and splenitis through
Bartonella growing in extracellular aggregates in the spleen
and liver. As the model is still relatively new, they did
not present any further characterization of the immune
response. However, it is clear that intraerythrocytic persis-
tence is characteristic of infections in immune-competent
hosts while endothelial/periendothelial persistence leading to
vasoproliferation is characteristic of an infection in immune-
compromised hosts [29].
5. Pathophysiology of
Bartonella Disease/Lesions in
Immunocompromised Hosts
5.1. Angiogenesis. Bacillary angiomatosis is the most com-
mon sequelae of B. quintana and B. henselae infections
in patients with cell-mediated immunodeficiency such as
HIV and posttransplant patients on immunosuppressive
therapy [9, 23, 30]. B. henselae and B. quintana induce their
characteristic vasoproliferative lesion, bacillary angiomato-
sis, or peliosis, in immunosuppressed patients, by direct and
indirect eﬀects on endothelial cells.
Whereasmost pathogenic bacteria achieve tissue destruc-
tion and wider dissemination by inducing apoptosis on host
cells, B. henselae and B. quintana infections persist within
periendothelial extracellular matrix resulting in sustained,
localized bacterial replication within collagen tissue [29].
This localized bacterial replication facilitates an antiapop-
totic state in endothelial cells by secreting eﬀector proteins
(BepA and BepA2) which bind to the endothelial membrane
receptor. The ensuing transmembrane signal transduction
results in high cytoplasmic cAMP levels. The high cAMP
levels upregulate cAMP responsive genes and induce an
antiapoptotic state in the endothelial cells, resulting in their
proliferation [31]. In addition, Schmid et al. in the same
experiment showed that BepA can inhibit cytotoxic T-cell-
mediated apoptosis of endothelial cells infected by B. henselae
and B. quintana. A further analysis of the antiapoptotic
mechanisms of some B. henselae strains isolated from HIV-
infected patients revealed that an anti-apoptotic state may
be eﬀected through B. henselae strain-specific upregulation
of antiapoptotic or downregulation of proapoptotic factors
that work through the mitochondrial intrinsic apoptotic
pathway [32]. As noted earlier, Interferon-alfa and IL-4 in
chronic Bartonella infections may play a role, albeit unclear,
in the development of bacillary angiomatosis given that
elevated levels have been reported both animal [27] and
human studies of the bacillary angiomatsois [25], but not in
immune-competent subjects with CSD [25].
NF-κB is also upregulated by Bartonella, resulting in
increased leukocyte rolling and adhesion and causes a proin-
flammatory environment [12]. Additional research is needed
to explore this link between some B. henselae strains that
infect HIV patients and vasoproliferation and inflammation.
Such work may shed more light into pathogenicity of
B. henselae and host susceptibility factors in HIV-positive
patients.
6. Immunocompromise Induced by
Bartonella Infections
B. bacilliformis itself induced an immunocompromised state.
Although B. bacilliformis is not widespread in distribution
and has not been described as a cause of bacillary angiomato-
sis or hepatic peliosis in immunocompromised patients, it
is notable that the acute bacteremic phase of B. bacilliformis
causes significant immunosuppression by overloading the
reticuloendothelial system. These patients are predisposed to
infections such as salmonella and tuberculosis [28].
7. Clinical Features of Bartonella Infections in
Immunocompromised Hosts
Bartonella infections caused by B. henselae or B. quintana
in the immunocompromised host may be characterized
by fever of unknown origin, culture-negative endocarditis,
osteomyelitis, or angioproliferative lesions that may aﬀect
virtually any organ system, but have a predilection for the
skin, liver, and spleen.
7.1. Clinical Features of Bartonella Infections in HIV-Infected
Patients. Bacillary angiomatosis lesions and fever are the
most common manifestation of B. henselae or B. quintana
infection in HIV/AIDS patients [3, 9]. The lesions appear as
cutaneous nodular vascular lesions but may also be found
in a variety of organs including the GI-tract where they
may cause hematemesis [33–35], genitourinary system [36],
and other organs including heart, spleen, bones, and central
nervous system. The diﬀerential diagnosis for bacillary
angiomatosis includes Kaposi’s sarcoma, angiosarcoma, and
pyogenic granuloma.
Similar vascular lesions are seen in both bacillary
peliosis and splenitis. Patients present with hepato- and/or
splenomegaly as blood filled cysts proliferate in these organs.
Confirming the diagnosis can be challenging as serology
has a 50–95% sensitivity and demonstrates cross-reaction
between Bartonella, Coxiella, and Chlamydia species. Results
from tissue culture are not always positive and take a long
time given the fastidious nature of the bacterium. PCR is
favored as a faster, sensitive, and specific diagnostic test
[37, 38].
7.2. Clinical Features of Bartonella Infections in Transplant
Patients. Persistent fever following close contact with cats is
the most common presenting symptom among posttrans-
plant patients who are infected with B. henselae [39]. B.
henselae infection was complicated by acute graft rejection in
2 renal transplant patients [40]. It is unclear if this rejection
was a random occurrence or if it is associated with some
unknown eﬀect of B. henselae on decreasing the donor
tolerance of the graft or enhancing graft antigenicity. In
liver transplant patients, B. henselae can present with hepatic
masses [41], hepatic granulomas [42, 43], or disseminated
disease [44].
7.3. Clinical Features of Bartonella Infection in Homeless
Patients with Chronic Alcoholism. Subacute, culture-negative
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endocarditis is the most common clinical presentation of
B. quintana (less so B. henselae) infection among homeless
patients with chronic alcoholism [4, 45, 46]. Risk factors for
Bartonella endocarditis include preexisting valvular lesions
and exposure to human body lice.
B. quintana may be cultured from the blood, but given
the prolonged time required for culture, other diagnostic
tests are preferred. An indirect immunofluorescent IgG
antibody test directed against Bartonella species with titer
of 1 : 800 or higher has a 95% positive predictive value for
diagnosing Bartonella endocarditis [47]. Diagnosis is usually
confirmed by performing PCR testing on plasma or tissue
samples following DNA extraction [6].
8. Conclusion
Bartonella species are important zoonotic agents of human
disease. Immunocompromised hosts are more susceptible
to infection from B. henselae or B. quintana which results
in a more severe clinical picture as compared with the
normal host. More recent work explores role of cytokines
and chemokines in subverting the immune system, and sub-
sequently a persistent infection characterized by vasoprolif-
eration in immunocompromised humans. The mechanisms
of establishing infection and immune evasion in immuno-
compromised hosts are still incompletely understood and are
areas where further studies are needed.
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